Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

Related Content:

ASCOLung CancerImmuno Oncology

Study Results Appear to Support Larotrectinib Use in NTRK+ Lung Cancer

Study Shows Increase in Lung Cancer Mortality, Decrease in Diagnosis During COVID-19 Pandemic

FDA Lifts Clinical Hold on Phase 1/2 Trial Evaluating BPX-601 for Metastatic Pancreatic, Prostate Cancer